Getting better mileage with logically primed CARs

Laurence C Chen¹, Andrew J Hou¹, Yvonne Y Chen²

Affiliations

¹ Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
² Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA 90095, USA. Electronic address: yvchen@ucla.edu.

PMID: 35590214
DOI: 10.1016/j.medj.2021.06.002

Free article

Comment

Getting better mileage with logically primed CARs

Laurence C Chen et al. Med. 2021.

Free article

. 2021 Jul 9;2(7):785-787.

doi: 10.1016/j.medj.2021.06.002.

Authors

Laurence C Chen¹, Andrew J Hou¹, Yvonne Y Chen²

Affiliations

¹ Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
² Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA 90095, USA. Electronic address: yvchen@ucla.edu.

PMID: 35590214
DOI: 10.1016/j.medj.2021.06.002

Abstract

Although remarkably successful against liquid tumors, chimeric antigen receptor (CAR)-T cell therapy has been stymied by solid tumors, limited by inadequate specificity and poor efficacy. Pairing synthetic Notch (synNotch) receptors with CARs, Choe et al. and Hyrenius-Wittsten et al. engineer T cells that more precisely and potently combat solid tumors.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Y.Y.C. and A.J.H. are inventors on patent applications that are unrelated to the work discussed here but whose value may be affected by the publication of this work. L.C.C. declares no competing interests.

Comment on

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.
Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA. Choe JH, et al. Sci Transl Med. 2021 Apr 28;13(591):eabe7378. doi: 10.1126/scitranslmed.abe7378. Sci Transl Med. 2021. PMID: 33910979 Free PMC article.
SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G, Liu B, Roybal KT. Hyrenius-Wittsten A, et al. Sci Transl Med. 2021 Apr 28;13(591):eabd8836. doi: 10.1126/scitranslmed.abd8836. Sci Transl Med. 2021. PMID: 33910981 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Getting better mileage with logically primed CARs

Affiliations

Getting better mileage with logically primed CARs

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical